eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
3-4/2006
vol. 31
 
Share:
Share:
more
 
 

Clinical immunology
The assessment of caspase activation during apoptosis of malignant cells in B-cell chronic lymphocytic leukaemia

Monika Podhorecka
,
Anna Dmoszynska

Centr Eur J Immunol 2006; 31 (3-4): 84-86
Online publish date: 2007/01/16
Article file
- The assessment.pdf  [0.10 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

B-cell chronic lymphocytic leukaemia (B-CLL) is characterised by the accumulation of malignant CD5+ B cells, in which. dysregulation of apoptosis rather than increased proliferation rate seems to play the crucial role [1, 2]. During apoptosis the activation of cysteine-aspartic acid-specific proteases (caspases) is the critical event, initiating the irreversible steps of cell demise. Even though there are some reports concerning caspase activation in B-CLL apoptosis the importance of this process in spontaneous and drug-induced cell death of malignant cells should be elucidated yet. The differentiation of the main ways of caspase activation
– external (via death receptors) and internal (mitochondrial) seems to be of great importance.
In this study we investigated the activation of caspases in B-CLL cells exposed to apoptosis both spontaneous and induced via external and internal pathway. The experiments were done in peripheral blood (PB) and bone marrow (BM) samples obtained from newly diagnosed, previously untreated B-CLL patients. We used the method based on detection of activated caspase with use of FAM-VAD-FMK that is the fluorochrome labelled inhibitors of caspases and is considered as a pan-caspase marker [3, 4].

Material and methods


Cell separation

PB and BM mononuclear cells obtained from 5 B-CLL patients were isolated by density gradient centrifugation (Lymphoprep, Nycomed Pharma, Norway) and resuspended at a concentration of 2x106 cells/ml in culture medium consisted of RPMI 1640 with 1% 2mM L-glutamine, 1% antibiotics (penicillin and streptomycin), 10% heat-inactivated fetal calf serum (FCS). All reagents used were purchased from Sigma, Germany. The cultures were maintained at 37°C in an atmosphere of 5% CO2 in air.

Induction of apoptosis

The B-CLL cells were cultured without apoptosis inductors to assess the spontaneous apoptosis. To induce apoptosis the cells were treated either with 0.15 µM of DNA topoisomerase I inhibitor camptothecin (CPT) or with
a combination of 0.3 nM tumour necrosis factor-a (TNF-α) and 5 µM cycloheximide (CHX), all from Sigma, Germany. Cells from all samples were harvested after 24 and 48 h of incubation and submitted to further procedures.

Cell staining

The fluorochrome labelled caspase inhibitor FAM-VAD--FMK that is considered as a pan-caspase marker was obtained as a component of CaspaTag Caspase Activity Kit (Intergen Company, USA). Before cell staining FAM-VAD--FMK was dissolved in dimethyl sulfoxide (DMSO, Sigma) to obtain 150 x concentrated (stock) solution. The aliquots of the stock solution were stored at -20°C in the dark. Before using the stock solution was diluted 1:5 in PBS to obtain 30 x working solution. The B-CLL cells in concentration of 106/ml were added to 10 µl of 30x working dilution of FAM-VAD-FMK and then incubated for 1 hour at 37°C under 5% CO2. After incubation time the cells were washed twice with 1x working Dilution Wash Buffer according to manufacture’s instruction. 2 µl of propidium iodide (PI) solution was added to cell suspension prior to flow cytometry acquisition.

Flow cytometry analysis

The bicolor flow cytometry technique by FACSCalibur (Becton Dickinson, USA) instrument and Cell Quest Software for data analysis were used. The green fluorescence on FL1 channel and red fluorescence (PI) on the FL3 channel were measured. Then a log FL1 (X-axis) versus log FL3
(Y-axis) dot plot was generated and the analysis in the quadrant cursors was performed.
Statistical analysis
The statistical analysis was done with use of Wilcoxon test (STATISTICA 6.0).

Results

We analysed the samples both of PB and BM in which the mean percentage of CD19+/CD5+ cells was comparable (75.07% and 73.60%, respectively).
All samples tested in the study revealed the presence of four distinct cell subpopulations, which differed in binding of VAD and PI (figure 1). Non-apoptotic cells showed neither VAD nor PI fluorescence (FLICA-PI-). The cells in early phase of apoptosis were VAD+PI-. VAD+PI+ and VAD-PI+ cells represented two consecutive phases of the “necrotic stage” of apoptosis. In further analysis we concerned the group of VAD+/PI- points as the best indicator of apoptotic cells. The results presenting as mean values are shown in table 1.
The spontaneous apoptosis was detected in both PB and BM samples in time-dependent analysis. There was the significantly higher percentage of VAD+/PI- cells in PB than BM samples both at 24 and 48 h. We detected an increase of apoptotic cells number in PB and BM after induction of apoptosis by both TNF-α and CPT. In PB and BM culture with CPT we observed significantly higher number of VAD+/PI- cells at 48 h in comparison to TNF-α-culture. The percentage of apoptotic cells in PB culture with CPT was higher than in BM, while there was no difference between PB and BM in TNF-α-culture.

Discussion

The obtained results indicate the time-dependent caspase activation during spontaneous and induced apoptosis of
B-CLL cell. Comparing the receptor and mitochondrial way of apoptosis induction we can presume that although both ways cause caspase activation, the level of caspase activation is higher after mitochondrial induction. The rate of mitochondrial-induced apoptosis in PB cells seems to be higher than in BM. The differences between the percentage of CD19+/CD5+ of PB and BM were not statistically significant, thus differences of apoptosis rate between these two cell environments seem not to be connected with percentage of malignant cells.
There are some reports concerning caspase activation during spontaneous or induced apoptosis of B-CLL PB cells based mainly on Western blot analysis. The activation of caspase-9 involving in mitochondrial way of apotosis followed by actvation of effector caspases-3 and -7, as well as caspases-8 activation involving in receptor way in
B-CLL cells was reported by Almond et al. [5]. Perez-Galan et al. [6] detected caspase-3,-7-,8, and -9 activation induced by cladribine. King et al. [7] reported activation of caspase-3 and -7 and the processing of caspase-8 in spontaneous and drug-induced B-CLL apoptosis. Jones et al. [8] detected procaspase-8 processing induced by chlorambucil, fludarabine or g radiation. High level of caspase-8 in
B-CLL in conjunction with resistance to Fas/FasL signaling system is interesting and require elucidation [9]. On the contrary MacFarlane et al. [10] reported resistance of B-CLL cells to TRAIL induced-apotosis connected with little or no caspase-8 processing.
Our results, similarly to those presented above, indicated on involvement of caspases in apoptosis process of B-CLL cells obtained from PB. Additionally, for the first time the analysis of B-CLL cells obtained from BM was presented. We detected the higher rate of caspase activation during spontaneous and mitochondrial induced apoptosis in PB than in BM, that may indicate the differences in apoptosis process depending on cell environment. In view of controversial results reported by other authors, the differentiation between receptor and mitochondrial way of apoptosis seems to be difficult. We detected caspase activation both in receptor and mitochondrial induction of apoptosis, but with higher rate in mitochondrial one, that may suggest dominance of this mechanism in B-CLL, however, activation of caspases connected with receptor way cannot be excluded.


Acknowledgment

This work was supported by a research grant No 2PO5B 12026 from Polish State Committee for Scientific Research

References

1. Calligaris-Cappio F, Hamblin TJ (1999): B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17: 399-408.
2. Hamblin TJ, Oscier DG (1997): Chronic lymphocytic leukemia: the nature of the leukaemic cells. Blood Rev 11: 119-28.
3. Bedner E, Smolewski P, Amstad P, et al. (2000): Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): correlation with DNA fragmentation. Exp Cell Res 259: 308-313.
4. Smolewski P, Grabarek J, Lee BW, et al. (2002): Kinetics of HL-60 cell entry to apoptosis during treatment with TNF-αlpha or camptothecin assayed by the stathmo-apoptosis method. Cytometry 47: 143-149.
5. Almond JB, Snowden RT, Hunter A, et al.(2001): Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia 15: 1388-1397.
6. Perez-Galan P, Marzo I, Giraldo P, et al. (2002): Role of caspases and apoptosis-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphocytic leukemia. Leukemia 16: 2106-2114.
7. King D, Pringle JH, Hutchinson M, et al. (1998): Processing/activation of caspases, -3 and -7 and -8 but not caspase-2, in the induction of apoptosis in B-chronic lymphocytic leukemia cells. Leukemia 12: 1553-1560.
8. Jones DT, Ganeshaguru K, Virchis AE, et al. (2001): Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood 98: 2800-2807.
9. Roue G, Lancry L, Duquesne F, et al. (2001): Upstream mediators of the Fas apoptotic transduction pathway are defective in B-chronic lymphocytic leukemia. Leuk Res 25: 967-980.
10. MacFarlane M, Harper N, Snowden RT, et al. (2002): Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21: 6809-6818.
Copyright: © 2007 Polish Society of Experimental and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.